23.64
price up icon4.65%   1.05
after-market After Hours: 23.70 0.06 +0.25%
loading
Beam Therapeutics Inc stock is traded at $23.64, with a volume of 1.62M. It is up +4.65% in the last 24 hours and down -30.65% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$22.59
Open:
$22.5
24h Volume:
1.62M
Relative Volume:
1.11
Market Cap:
$2.36B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-13.06
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
-13.79%
1M Performance:
-30.65%
6M Performance:
-9.22%
1Y Performance:
-32.15%
1-Day Range:
Value
$22.50
$24.32
1-Week Range:
Value
$22.50
$28.34
52-Week Range:
Value
$20.84
$36.75

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
Name
Beam Therapeutics Inc
Name
Phone
857-327-8775
Name
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Employee
483
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
BEAM's Discussions on Twitter

Compare BEAM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BEAM
Beam Therapeutics Inc
23.64 2.36B 352.57M -143.01M -153.40M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
512.52 131.61B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
672.36 73.51B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
619.97 37.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.44 32.81B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
266.26 28.62B 3.81B -644.79M -669.77M -6.24

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-10-25 Upgrade Scotiabank Sector Perform → Sector Outperform
Jan-29-25 Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-06-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-16-24 Initiated Scotiabank Sector Outperform
Jul-23-24 Initiated H.C. Wainwright Buy
Jan-29-24 Upgrade JP Morgan Neutral → Overweight
Dec-15-23 Downgrade BofA Securities Buy → Neutral
Dec-08-23 Downgrade Jefferies Buy → Hold
Oct-20-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-20-23 Downgrade Leerink Partners Outperform → Market Perform
Mar-21-23 Initiated Bernstein Mkt Perform
Feb-01-23 Initiated Cantor Fitzgerald Overweight
Dec-20-22 Upgrade BMO Capital Markets Market Perform → Outperform
Dec-13-22 Initiated Citigroup Buy
Jun-17-22 Initiated BMO Capital Markets Market Perform
Apr-28-22 Initiated Credit Suisse Neutral
Jan-05-22 Initiated Guggenheim Buy
Oct-19-21 Initiated SVB Leerink Outperform
Sep-24-21 Resumed Stifel Buy
Sep-10-21 Initiated BofA Securities Buy
May-11-21 Initiated Redburn Buy
May-04-21 Initiated RBC Capital Mkts Sector Perform
Mar-01-21 Downgrade Barclays Overweight → Equal Weight
Feb-16-21 Initiated Wells Fargo Overweight
Jan-29-21 Downgrade JP Morgan Overweight → Neutral
Jan-06-21 Initiated Stifel Hold
Aug-05-20 Initiated William Blair Outperform
Mar-02-20 Initiated Barclays Overweight
Mar-02-20 Initiated JP Morgan Overweight
Mar-02-20 Initiated Jefferies Buy
Mar-02-20 Initiated Wedbush Outperform
View All

Beam Therapeutics Inc Stock (BEAM) Latest News

pulisher
Mar 19, 2025

Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily

Mar 19, 2025
pulisher
Mar 18, 2025

3 Gene Therapy Stocks to Watch Amid Industry Turmoil - Schaeffers Research

Mar 18, 2025
pulisher
Mar 17, 2025

Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study - MSN

Mar 17, 2025
pulisher
Mar 16, 2025

Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years? - Insider Monkey

Mar 16, 2025
pulisher
Mar 16, 2025

BEAM Down Despite Positive Initial Data From Genetic Disorder Study - MSN

Mar 16, 2025
pulisher
Mar 14, 2025

Wedbush Research Analysts Raise Earnings Estimates for BEAM - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Critical Survey: Adaptive Biotechnologies (NASDAQ:ADPT) vs. Beam Therapeutics (NASDAQ:BEAM) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Citi lifts Beam Therapeutics stock price target to $64 - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Citi lifts Beam Therapeutics stock price target to $64 By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Beam Therapeutics Reports Clinical Proof-Of-Concept Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Trial - CRISPR Medicine News

Mar 12, 2025
pulisher
Mar 12, 2025

Beam Therapeutics stock target holds at $37 on positive trial data - Investing.com Canada

Mar 12, 2025
pulisher
Mar 11, 2025

Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market - Dealbreaker

Mar 11, 2025
pulisher
Mar 11, 2025

Beam Therapeutics stock target holds at $37 on positive trial data By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 11, 2025

Beam Therapeutics: Promising Phase 1 Results for BEAM-302 in AATD, Hold Rating Due to Long-term Efficacy Uncertainty - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Beam Therapeutics (NASDAQ:BEAM) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

BMO Capital maintains Outperform on Beam Therapeutics stock - MSN

Mar 11, 2025
pulisher
Mar 11, 2025

Wainwright holds Beam stock Buy rating, $80 target after trial data - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

In Vivo Base Editing Gets Boost with Positive Initial Data Announced by Beam Therapeutics - Genetic Engineering & Biotechnology News

Mar 11, 2025
pulisher
Mar 11, 2025

Proficio Capital Partners LLC Makes New $406,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Beam Therapeutics, Lennar, Redfin - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Beam Therapeutics (NASDAQ:BEAM) Upgraded by Scotiabank to “Sector Outperform” Rating - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Beam Therapeutics’ (BEAM) Outperform Rating Reaffirmed at Wedbush - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Beam Therapeutics (NASDAQ:BEAM) Upgraded by Jones Trading to Buy Rating - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Scotiabank Upgrades Beam Therapeutics (BEAM) - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Gets Important Proof Of Concept For AATD Therapy - Citeline News & Insights

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics: Single-Base Editing Seems To Work - Seeking Alpha

Mar 10, 2025
pulisher
Mar 10, 2025

Beam drops 9% on phase 1/2 data for genetic lung disease candidate - Seeking Alpha

Mar 10, 2025
pulisher
Mar 10, 2025

JonesResearch upgrades Beam Therapeutics to Buy on de-risking data - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Promising Phase 1/2 Trial Results for Beam Therapeutics’ BEAM-302 Bolster Confidence and Support $80 Price Target - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Scotiabank Upgrades Beam Therapeutics to Sector Outperform From Sector Perform, $40 Price Target - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics’ BEAM-302 Shows Promising Phase I/II Results, Earning Buy Rating from Analyst - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now? - Insider Monkey

Mar 10, 2025
pulisher
Mar 10, 2025

Beam launches $500m financing on base-editing trial data - pharmaphorum

Mar 10, 2025
pulisher
Mar 10, 2025

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity - Benzinga

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics Prices $500 Million Share, Warrant Offering -March 10, 2025 at 08:15 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics says CRISPR treatment shows encouraging results in lung condition - STAT

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics rises on early-stage trial results for gene editing therapy - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics Announces Positive Initial Data For BEAM-302 In Alpha-1 Antitrypsin Deficiency - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics’ BEAM-302 Shows Promising Efficacy and Safety in AATD Treatment, Earning Buy Rating - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics stock soars on positive BEAM-302 trial data - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics stock soars on positive BEAM-302 trial data By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics Shares Surge on Promising Trial Data - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics Reports Positive Phase 1/2 Trial Data - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics Reprots Positive Initial Phase 1/2 Data For BEAM-302 In AATD - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics BEAM-302 Was Well Tolerated At All Dose Levels -March 10, 2025 at 06:11 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics Reports Promising Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Clinical Trial - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation - The Manila Times

Mar 10, 2025
pulisher
Mar 10, 2025

Beam Therapeutics announces ‘positive’ data from study of BEAM-302 - TipRanks

Mar 10, 2025

Beam Therapeutics Inc Stock (BEAM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$78.94
price up icon 2.53%
$318.85
price up icon 1.51%
$33.41
price up icon 0.00%
$20.11
price up icon 1.41%
$99.27
price up icon 0.31%
biotechnology ONC
$266.26
price up icon 1.87%
Cap:     |  Volume (24h):